Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

CompletedOBSERVATIONAL

Enrollment

135

Participants

Timeline

Start Date

December 5, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

November 30, 2023

Conditions

Polypoidal Choroidal VasculopathyChoroidal NeovascularizationAge-Related Macular Degeneration

Interventions

DRUG

Intravitreal aflibercept injection

Intravitreal injection of aflibercept (0.2 mg / 0,05 ml; Bayer Co. Ltd.,)

Trial Locations (1)

Jae Hui Kim, Seoul

All Listed Sponsors

lead

Kim's Eye Hospital

OTHER